BACKGROUND: Identification of the Th17 T cell subset as important mediators of host defense and pathology prompted us to determine their susceptibility to human immunodeficiency virus (HIV) infection. METHODS AND RESULTS: We found that a sizeable portion of Th17 cells express HIV coreceptor CCR5 and produce very low levels of CCR5 ligands macrophage inflammatory protein (MIP)-1alpha and MIP-1beta. Accordingly, CCR5(+) Th17 cells were efficiently infected with CCR5-tropic HIV and were depleted during viral replication in vitro. Remarkably, HIV-infected individuals receiving treatment had significantly reduced Th17 cell counts, compared with HIV-uninfected subjects, regardless of viral load or CD4 cell count, whereas treatment-naive subjects had normal levels. However, there was a preferential reduction in CCR5(+) T cells that were also CCR6 positive, which is expressed on all Th17 cells, compared with CCR6(-)CCR5(+) cells, in both treated and untreated HIV-infected subjects. This observation suggests preferential targeting of CCR6(+)CCR5(+) Th17 cells by CCR5-tropic viruses in vivo. Th17 cell levels also inversely correlated with activated CD4(+) T cells in HIV-infected individuals who are receiving treatment. CONCLUSIONS: Our findings suggest a complex perturbation of Th17 subsets during the course of HIV disease potentially through both direct viral infection and virus indirect mechanisms, such as immune activation.
BACKGROUND: Identification of the Th17 T cell subset as important mediators of host defense and pathology prompted us to determine their susceptibility to humanimmunodeficiency virus (HIV) infection. METHODS AND RESULTS: We found that a sizeable portion of Th17 cells express HIV coreceptor CCR5 and produce very low levels of CCR5 ligands macrophage inflammatory protein (MIP)-1alpha and MIP-1beta. Accordingly, CCR5(+) Th17 cells were efficiently infected with CCR5-tropic HIV and were depleted during viral replication in vitro. Remarkably, HIV-infected individuals receiving treatment had significantly reduced Th17 cell counts, compared with HIV-uninfected subjects, regardless of viral load or CD4 cell count, whereas treatment-naive subjects had normal levels. However, there was a preferential reduction in CCR5(+) T cells that were also CCR6 positive, which is expressed on all Th17 cells, compared with CCR6(-)CCR5(+) cells, in both treated and untreated HIV-infected subjects. This observation suggests preferential targeting of CCR6(+)CCR5(+) Th17 cells by CCR5-tropic viruses in vivo. Th17 cell levels also inversely correlated with activated CD4(+) T cells in HIV-infected individuals who are receiving treatment. CONCLUSIONS: Our findings suggest a complex perturbation of Th17 subsets during the course of HIV disease potentially through both direct viral infection and virus indirect mechanisms, such as immune activation.
Authors: Estelle Bettelli; Yijun Carrier; Wenda Gao; Thomas Korn; Terry B Strom; Mohamed Oukka; Howard L Weiner; Vijay K Kuchroo Journal: Nature Date: 2006-04-30 Impact factor: 49.962
Authors: Ivaylo I Ivanov; Brent S McKenzie; Liang Zhou; Carlos E Tadokoro; Alice Lepelley; Juan J Lafaille; Daniel J Cua; Dan R Littman Journal: Cell Date: 2006-09-22 Impact factor: 41.582
Authors: Enrique Gonzalez; Hemant Kulkarni; Hector Bolivar; Andrea Mangano; Racquel Sanchez; Gabriel Catano; Robert J Nibbs; Barry I Freedman; Marlon P Quinones; Michael J Bamshad; Krishna K Murthy; Brad H Rovin; William Bradley; Robert A Clark; Stephanie A Anderson; Robert J O'connell; Brian K Agan; Seema S Ahuja; Rosa Bologna; Luisa Sen; Matthew J Dolan; Sunil K Ahuja Journal: Science Date: 2005-01-06 Impact factor: 47.728
Authors: Marieke A Hoeve; Nigel D L Savage; Tjitske de Boer; Dennis M L Langenberg; René de Waal Malefyt; Tom H M Ottenhoff; Frank A W Verreck Journal: Eur J Immunol Date: 2006-03 Impact factor: 5.532
Authors: Kyle I Happel; Patricia J Dubin; Mingquan Zheng; Nico Ghilardi; Christie Lockhart; Lee J Quinton; Anthony R Odden; Judd E Shellito; Gregory J Bagby; Steve Nelson; Jay K Kolls Journal: J Exp Med Date: 2005-09-12 Impact factor: 14.307
Authors: C Loiseau; M Requena; M Mavigner; M Cazabat; N Carrere; B Suc; K Barange; L Alric; B Marchou; P Massip; J Izopet; P Delobel Journal: Mucosal Immunol Date: 2016-02-17 Impact factor: 7.313